TY - JOUR
T1 - Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis
AU - Reginster, Jean Yves
AU - Cooper, Cyrus
AU - Hochberg, Marc
AU - Pelletier, Jean Pierre
AU - Rizzoli, René
AU - Kanis, John
AU - Abadie, Eric
AU - Maheu, Emmanuel
AU - Brandi, Maria Luisa
AU - Devogelaer, Jean Pierre
AU - Branco, Jaime
AU - Herrero-Beaumont, Gabriel
AU - D'Hooghe, Pieter
AU - Bruyère, Olivier
PY - 2015/5/1
Y1 - 2015/5/1
N2 - Despite the near concurrent publication by influential scientific organizations, there are important differences in interpretation of the evidence base and the conclusions derived from the recent Osteoarthritis Research Society International (OARSI) guidelines for the management of knee osteoarthritis, the American College of Rheumatology (ACR) guidelines (concerning also hip and hand osteoarthritis) and the algorithm recommendations by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). This is particularly evident for the drug class of symptomatic slow-acting drugs in osteoarthritis. In this paper, we highlight these differences and try to understand where they derive from, proposing an evidence-based interpretation.
AB - Despite the near concurrent publication by influential scientific organizations, there are important differences in interpretation of the evidence base and the conclusions derived from the recent Osteoarthritis Research Society International (OARSI) guidelines for the management of knee osteoarthritis, the American College of Rheumatology (ACR) guidelines (concerning also hip and hand osteoarthritis) and the algorithm recommendations by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). This is particularly evident for the drug class of symptomatic slow-acting drugs in osteoarthritis. In this paper, we highlight these differences and try to understand where they derive from, proposing an evidence-based interpretation.
KW - Chondroitin
KW - Glucosamine
KW - Hyaluronic acid
KW - Osteoarthritis
KW - Symptomatic slow-acting drugs in osteoarthritis
UR - http://www.scopus.com/inward/record.url?scp=84928177249&partnerID=8YFLogxK
U2 - 10.1185/03007995.2015.1027183
DO - 10.1185/03007995.2015.1027183
M3 - Review article
C2 - 25753599
AN - SCOPUS:84928177249
SN - 0300-7995
VL - 31
SP - 1041
EP - 1045
JO - Current Medical Research and Opinion
JF - Current Medical Research and Opinion
IS - 5
ER -